Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Beyondspring Inc BYSI

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.


NDAQ:BYSI - Post by User

Comment by dmacdon Jan 19, 2022 11:51am
125 Views
Post# 34333018

RE:Compelling despite Headwinds

RE:Compelling despite Headwinds Well if it goes to $3/sh or cash valuation then it is time for me to double down. I did not think that chance would come. The market is getting past stupid now. Beyond team has had a tough break with the FDA. I wonder if their China presence played a factor. The market deserves some clarity on the issue that the FDA has so hopefully we get that soon. China progression is still in play and the milestone payments are worth more than the market cap at the moment. This valuation appears to be a bad joke but fortunately no cash neeeds to be raised so bring it on. GLTA. 
<< Previous
Bullboard Posts
Next >>